UGT2B15 is a phase II detoxification enzyme that catalyzes the conjugation of diverse substrates with glucuronic acid to facilitate their elimination 1. The enzyme demonstrates broad substrate specificity, metabolizing endogenous steroid hormones including testosterone, dihydrotestosterone, androsterone, and estradiol, as well as xenobiotic compounds such as phenolic compounds, coumarins, and flavonoids 1. UGT2B15 exhibits widespread tissue expression in liver, kidney, testis, mammary gland, placenta, prostate, and other organs 1. The gene contains a common polymorphism (D85Y) that affects enzyme activity, with the Y85 variant showing higher catalytic efficiency 1. Expression is developmentally regulated, beginning in late fetal life at approximately 18% of adult levels and reaching peak expression in early infancy 2. UGT2B15 contributes significantly to acetaminophen glucuronidation, with polymorphisms affecting clearance rates 3. The enzyme's expression is subject to complex regulation by transcription factors including CAR, PXR, and ESR1 4, and post-transcriptional control by microRNAs such as miR-376c 5 and miR-129-5p through interaction with long noncoding RNA LINC00574 6. This regulation is particularly important in prostate cancer cells where UGT2B15 modulates androgen signaling 5.